tiprankstipranks
pc:biosc

32 Biosciences

A gastrointestinal-focused biotechnology company developing therapies and discovery tools to restore and protect the gut mucosal-immune system. The company is advancing CS-0003, a first-in-class Mucosal-Immune Modulator, and GB, a metabolomics-based GI discovery platform, with an initial focus on preventing GI surgical site infections and potential expansion into IBD and prevention of colon cancer recurrence.

Leadership & Board

Currently, no data available

Latest Estimated Valuation

Estimated Valuation
Estimated Valuation
Total Amount Raised$40M
Total Amount Raised$40M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$40M
Latest Funding Amount$40M
Latest Funding RoundSeries A
Latest Funding RoundSeries A
Post-Money Valuation
Post-Money Valuation

Funding Round

Funding Date
Funding Round
Amount Raised
Post-Money Valuation
Jan 08, 2026
Series A
$40.00M

Related News and Analysis